Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine [for patients with previously treated
well-differentiated thyroid cancer and evidence of residual disease based on serum
thyroglobulin (Tg) level] whether positron emission tomography-computed tomography (PET-CT)
fusion scanning performed after recombinant thyroid-stimulating hormone (TSH) (rTSH,
thyrotropin alfa for injection) will be more sensitive for the detection of disease sites
than PET-CT scanning without rTSH. The study will also determine if this information will
significantly alter the therapeutic approach in some patients.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Genzyme, a Sanofi Company Gustave Roussy, Cancer Campus, Grand Paris M.D. Anderson Cancer Center